The Experts below are selected from a list of 8886 Experts worldwide ranked by ideXlab platform
Vincent C. Ho - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of Pyoderma gangrenosum
Journal of the American Academy of Dermatology, 1996Co-Authors: Robert K.p. Chow, Vincent C. HoAbstract:Critical to the proper management of Pyoderma gangrenosum are correct diagnosis, identification and treatment of any underlying disorder, and the proper choice of topical and systemic therapy. Many agents are available for the treatment of Pyoderma gangrenosum. We review the current therapeutic options, their efficacy and side effects, and we offer some guidelines for their proper selection.
G Nicoletti - One of the best experts on this subject based on the ideXlab platform.
-
Pyoderma gangrenosum an updated review
Journal of The European Academy of Dermatology and Venereology, 2009Co-Authors: Eleonora Ruocco, S Sangiuliano, Antonietta Gerarda Gravina, Agnese Miranda, G NicolettiAbstract:Abstract Pyoderma gangrenosum is a rare, ulcerative, cutaneous condition. First described in 1930, the pathogenesis of Pyoderma gangrenosum remains unknown, but it is probably related to a hyperergic reaction. There are various clinical and histological variants of this disorder. Pyoderma gangrenosum often occurs in association with a systemic disease such as inflammatory bowel disease, rheumatologic disease, paraproteinaemia, or haematological malignancy. The diagnosis, mainly based on the clinical presentation and course, is confirmed through a process of elimination of other causes of cutaneous ulcers. Local treatment may be sufficient for mild disease, while for severe cases, systemic immunosuppressants are the mainstay. Long-term treatment with these agents is often required, but this can expose patients to adverse side-effects. Conflicts of interest None declared.
-
Pyoderma gangrenosum: an updated review
Journal of the European Academy of Dermatology and Venereology : JEADV, 2009Co-Authors: Eleonora Ruocco, S Sangiuliano, Antonietta Gerarda Gravina, Agnese Miranda, G NicolettiAbstract:Pyoderma gangrenosum is a rare, ulcerative, cutaneous condition. First described in 1930, the pathogenesis of Pyoderma gangrenosum remains unknown, but it is probably related to a hyperergic reaction. There are various clinical and histological variants of this disorder. Pyoderma gangrenosum often occurs in association with a systemic disease such as inflammatory bowel disease, rheumatologic disease, paraproteinaemia, or haematological malignancy. The diagnosis, mainly based on the clinical presentation and course, is confirmed through a process of elimination of other causes of cutaneous ulcers. Local treatment may be sufficient for mild disease, while for severe cases, systemic immunosuppressants are the mainstay. Long-term treatment with these agents is often required, but this can expose patients to adverse side-effects.
Conor P Delaney - One of the best experts on this subject based on the ideXlab platform.
-
management of peristomal Pyoderma gangrenosum
Diseases of The Colon & Rectum, 2005Co-Authors: Ravi P Kiran, Bridget Obrienermlich, Jean-paul Achkar, Victor W Fazio, Conor P DelaneyAbstract:PURPOSE: This study was designed to evaluate the presentation, management, and outcome of peristomal Pyoderma gangrenosum at a specialist colorectal unit and develop a strategy for therapy. METHODS: Patients with peristomal Pyoderma gangrenosum were identified from a prospectively accrued Institutional Review Board-approved stoma database. Data were collected regarding demographics, disease status, history of illness, time to healing, and treatments used from the database and by chart review. RESULTS: Sixteen patients presented between 1997 and 2002 with peristomal ulceration consistent with a diagnosis of peristomal Pyoderma gangrenosum. Diagnosis was predominantly clinically based on a classic presentation of painful, undermined peristomal ulceration. The underlying diagnosis was Crohn's disease in 11 patients, ulcerative colitis in 3, indeterminate colitis in 1, and posterior urethral valves in 1. At the time of development of peristomal Pyoderma gangrenosum, the underlying disease was active in 69 percent of patients. Stoma care, ulcer debridement with unroofing of undermined edges, and intralesional corticosteroid injection was associated with a 40 percent complete response rate and further 40 percent partial response rate. Of five patients who received infliximab, four (80 percent) responded to therapy. Complete response after all forms of therapy, including stoma relocation in seven patients, was 87 percent. CONCLUSIONS: Local wound management and enterostomal therapy are extremely important for patients with peristomal Pyoderma gangrenosum. Infliximab may provide a useful option for those failing other forms of medical therapy. Relocation of the stoma is reserved for persistent ulceration failing other therapies, because peristomal Pyoderma gangrenosum may recur at the new stoma site.
Robert K.p. Chow - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of Pyoderma gangrenosum
Journal of the American Academy of Dermatology, 1996Co-Authors: Robert K.p. Chow, Vincent C. HoAbstract:Critical to the proper management of Pyoderma gangrenosum are correct diagnosis, identification and treatment of any underlying disorder, and the proper choice of topical and systemic therapy. Many agents are available for the treatment of Pyoderma gangrenosum. We review the current therapeutic options, their efficacy and side effects, and we offer some guidelines for their proper selection.
Sally Bishop - One of the best experts on this subject based on the ideXlab platform.
-
Peristomal Pyoderma gangrenosum
Journal of The American Academy of Dermatology, 1992Co-Authors: Miriam Keltz, Mark Lebwohl, Sally BishopAbstract:Abstract A patient with Crohn's disease and peristomal Pyoderma gangrenosum is described. This patient is unique because she had a rapid response to intralesionally injected steroids. This treatment is ideal for peristomal Pyoderma gangrenosum because it is administered intermittently when the ostomy appliance is changed and it does not interfere with adhesion of the device. All 11 cases of peristomal Pyoderma gangrenosum described in the literature are reviewed.
